Few topics in preventive medicine have generated as much controversy, guideline confusion, and patient anxiety as prostate-specific antigen (PSA) screening for prostate cancer. The United States Preventive Services Task Force (USPSTF) issued a "D" (do not recommend) grade for PSA screening in 2012, triggering a sharp decline in testing that many oncologists argue contributed to increased rates of metastatic prostate cancer at diagnosis. In 2018, the USPSTF upgraded to a "C" recommendation (offer to men 55–69 after informed decision-making), and by 2025, a consensus is emerging that PSA-based screening with modern diagnostic refinements delivers meaningful mortality reduction with substantially reduced overtreatment compared to the era when a positive PSA reflexively triggered biopsy and most biopsied patients received definitive treatment.
The Evidence for PSA Screening
The European Randomized Study of Screening for Prostate Cancer (ERSPC), with 20-year follow-up data published in 2022, demonstrates a 25% reduction in prostate cancer mortality in the screened group — an absolute mortality reduction of 3.7 deaths per 1,000 men screened over 20 years. Crucially, the number needed to screen to prevent one death has improved dramatically with longer follow-up (from 1,000 at 9 years to 265 at 16 years), as the benefits of early detection compound over time. The Göteborg subcohort of ERSPC — using PSA testing every 2 years starting at age 50 — showed a 44% reduction in prostate cancer mortality.
Multiparametric MRI: Revolutionizing Diagnostic Accuracy
The introduction of multiparametric MRI (mpMRI) before prostate biopsy — now recommended by the AUA, EAU, and incorporated into NICE guidelines — has been the most significant advance in reducing overdiagnosis. The PROMIS trial demonstrated that mpMRI prior to biopsy could safely avoid biopsy in 27% of men and reduces detection of clinically insignificant cancer by 89% while missing only 3% of clinically significant tumors. The PRECISION trial showed mpMRI-targeted biopsy detected 38% more high-grade (Gleason ≥7) cancers and 89% fewer low-grade cancers than systematic 12-core biopsy — precisely the trade-off needed to reduce overtreatment. In-bore MRI-guided fusion biopsy platforms now enable >98% concordance between target and needle placement.
Active Surveillance: Managing Low-Risk Prostate Cancer Without Treatment
For the most common prostate cancer diagnosed through screening — low-risk (Gleason 6, PSA <10, cT1-T2) — active surveillance (AS) has become the preferred management strategy at most major cancer centers, replacing the reflexive radical prostatectomy or radiotherapy that defined the previous era. The ProtecT trial 10-year results confirmed that mortality from low-risk prostate cancer is less than 1% regardless of whether men receive immediate radical treatment or monitoring — but radical treatment causes significant rates of sexual dysfunction (66% vs 22%) and urinary incontinence. The Sunnybrook and PRIAS active surveillance programs have demonstrated 15-year metastasis-free survival exceeding 98% in low-risk patients on AS — firmly establishing surveillance as oncologically safe.
Novel Biomarkers Refining PSA
PSA's poor specificity (60–75% false positive rate for biopsy decision) has driven development of reflex tests that use a PSA result as a gateway to more specific biomarkers: the 4Kscore (four kallikrein panel), Prostate Health Index (PHI), SelectMDx (urine RNA markers), and ExoDx Prostate Intelliscore (urine exosome test) all outperform PSA alone for predicting high-grade cancer presence — with negative predictive values exceeding 95% for Gleason ≥7 cancer, enabling safe deferral of biopsy in low-risk men. Urologic practices and cancer screening programs should ensure their laboratory infrastructure supports these biomarker assays through our lab supplies catalog.
